Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Investigational Oral Candidate JOTROL™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter...
-
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD
-
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May ...
-
PharmAla announces signed definitive agreement to form a special purpose vehicle to spin out APA-01 entity for development, partnering with Diteba
-
PharmAla signs a binding letter of intent to spin out its APA-01 novel asset into a joint venture with Aluvaris and Diteba, with deal to close in June.
-
PharmAla files Q2 quarterly financials with increased customer deposits.
-
PharmAla is positioned to supply the US market with MDMA, and is advancing its next-generation patented safer MDMA product for human dosing this year.
-
PharmAla provides an update on Cortexa, its Australian joint venture with Vitura Health.
-
Pharmala announces a newly signed contract to supply a clinical trial, and the fulfillment of a previously announced trial.
-
PharmAla to receive clinical trial data from harvard-affiliated hospital in exchange for a drug donation